Urocortin II gene is highly expressed in mouse skin and skeletal muscle tissues: Localization, basal expression in corticotropin-releasing factor receptor (CRFR) 1-and CRFR2-null mice, and regulation by glucocorticoids

被引:65
作者
Chen, A [1 ]
Blount, A [1 ]
Vaughan, J [1 ]
Brar, B [1 ]
Vale, W [1 ]
机构
[1] Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA
关键词
D O I
10.1210/en.2003-1570
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Peptides encoded by the Urocortin (Ucn) II gene, also known as stresscopin-related peptide, were recently identified as new members of the corticotropin-releasing factor (CRF) family. Ucn II is a specific ligand for the type 2 CRF receptor (CRFR). We have demonstrated the peripheral distribution of mouse Ucn (mUcn) II transcripts by using specific mUcn II ribonuclease protection assays, RT-PCR, Southern hybridization, and DNA sequencing. Although Ucn II mRNA is widely expressed in a variety of peripheral tissues, we found it to be most highly expressed in the skin and skeletal muscle tissues. Using a specific RIA for mUcn II, we detected Ucn II-like immunoreactivity (ir) in acid extracts of mouse brain, muscle, and skin. Immunohistochemical studies revealed Ucn II-like ir in both skin epidermis and adnexal structures and in the skeletal muscle myocytes. Ucn II mRNA and ir were also observed in neonatal skeletal muscle cultures in which Ucn II was localized to the myotube. We found a significant increase in Ucn II mRNA levels in the skin, but not in skeletal muscle, of both CRFR1- and CRFR2-null mice compared with their wild-type littermates. We showed that administration of dexamethasone to mice resulted in a decrease of Ucn II mRNA levels in the back skin region 12 h after ip injections. Removal of the adrenal gland significantly increased the levels of Ucn II mRNA in the skin, and the levels were reduced back to normal levels after corticosterone replacement. Further examination of the distribution and regulation of CRFR2 and its specific ligand Ucn II in the skin and skeletal muscle tissues may reveal the manner by which the CRFR2 pathway is involved in the physiological responses to stress in these tissues and in other pathophysiologies of the skin and muscle.
引用
收藏
页码:2445 / 2457
页数:13
相关论文
共 63 条
  • [51] Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects
    Theoharides, TC
    Singh, LK
    Boucher, W
    Pang, XZ
    Letourneau, R
    Webster, E
    Chrousos, G
    [J]. ENDOCRINOLOGY, 1998, 139 (01) : 403 - 413
  • [52] Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1
    Timpl, P
    Spanagel, R
    Sillaber, I
    Kresse, A
    Reul, JMHM
    Stalla, GK
    Blanquet, V
    Steckler, T
    Holsboer, F
    Wurst, W
    [J]. NATURE GENETICS, 1998, 19 (02) : 162 - 166
  • [53] Urocortin, a corticotropin-releasing factor-related mammalian peptide, inhibits edema due to thermal injury in rats
    Turnbull, AV
    Vale, W
    Rivier, C
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 303 (03) : 213 - 216
  • [54] CHARACTERIZATION OF A 41-RESIDUE OVINE HYPOTHALAMIC PEPTIDE THAT STIMULATES SECRETION OF CORTICOTROPIN AND BETA-ENDORPHIN
    VALE, W
    SPIESS, J
    RIVIER, C
    RIVIER, J
    [J]. SCIENCE, 1981, 213 (4514) : 1394 - 1397
  • [55] Van Pett K, 2000, J COMP NEUROL, V428, P191, DOI 10.1002/1096-9861(20001211)428:2<191::AID-CNE1>3.0.CO
  • [56] 2-U
  • [57] UROCORTIN, A MAMMALIAN NEUROPEPTIDE RELATED TO FISH UROTENSIN-I AND TO CORTICOTROPIN-RELEASING FACTOR
    VAUGHAN, J
    DONALDSON, C
    BITTENCOURT, J
    PERRIN, MH
    LEWIS, K
    SUTTON, S
    CHAN, R
    TURNBULL, AV
    LOVEJOY, D
    RIVIER, C
    RIVIER, J
    SAWCHENKO, PE
    VALE, W
    [J]. NATURE, 1995, 378 (6554) : 287 - 292
  • [58] CHARACTERIZATION OF MELANIN-CONCENTRATING HORMONE FROM RAT HYPOTHALAMUS
    VAUGHAN, JM
    FISCHER, WH
    HOEGER, C
    RIVIER, J
    VALE, W
    [J]. ENDOCRINOLOGY, 1989, 125 (03) : 1660 - 1665
  • [59] VAUGHAN JM, 1989, METHOD ENZYMOL, V168, P588
  • [60] WAGNER U, 1985, GRUPPENDYNAMIK, V16, P5